Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Endocyte Shares Up More Than 100% In 2 Days, But Analyst Sees Even More Upside Possible

Courtesy of Benzinga.

Endocyte Shares Up More Than 100% In 2 Days, But Analyst Sees Even More Upside Possible

Shares of Endocyte, Inc. (NASDAQ: ECYT) were trading higher by more than 60 percent Tuesday afternoon at $5.82 on top of Monday’s monster triple-digit-percentage return gain, but some analysts see even more upside. Wedbush’s David Nierengarten upgraded Endocyte’s stock rating Neutral to Outperform with a price target boosted from $2 to $7 (see his track record here).

Endocyte’s stock has soared over the past two days after the company announced a new licensing deal to deliver a radioisotope cell-killing chemotherapy payload, FierceBiotech explained. The licensing agreement with Germany’s ABX focuses on the company’s Lu-PSMA-617 therapy, which could be used to treat approximately 80,000 patients in the late stages of the disease.

PSMA-617 could prove to have “broader opportunities and fewer hurdles” compared to Xofigo, which was approved in 2013.

“We note that Xofigo is only approved for patients with disease that has spread to the bones, and needs to be paired with another drug to address soft tissue disease, whereas PSMA-617 has shown activity in patients with PSMA+ disease in both bone and soft tissue,” the analyst wrote. “Xofigo, developed by Algeta (acquired by Bayer in 2013), is on track to exceed $400M in sales this year. We note that the success of Xofigo comes despite constraints in procuring 223Ra, as long half-life of parent (227Ac and 227Th isolated from a 231Pa source) limits supply; production of 177Lu is less restricted in comparison, with multiple routes of production identified.”

Related Links:

15 Biggest Mid-Day Gainers For Tuesday

Mid-Day Market Update: Dow Rises 70 Points; RedHill Biopharma Shares Slide

Latest Ratings for ECYT

Date Firm Action From To
Oct 2017 Wedbush Upgrades Neutral Outperform
Jun 2017 Cowen & Co. Downgrades Outperform Market Perform
Jun 2017 Wedbush Downgrades Outperform Neutral

View More Analyst Ratings for ECYT


View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Upgrades Price Target Analyst Ratings Movers Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!